<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915460</url>
  </required_header>
  <id_info>
    <org_study_id>C-98-838</org_study_id>
    <nct_id>NCT00915460</nct_id>
  </id_info>
  <brief_title>Open-Label Safety Extension Study of Avonex</brief_title>
  <official_title>An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect data on serious adverse events which occur during extended treatment with Avonex
      in subjects at high risk for developing multiple sclerosis (MS) and in subjects with
      secondary progressive MS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to collect data on serious adverse events which occur during extended treatment with AVONEX in subjects at high risk for developing MS and in subjects with secondary progressive MS.</measure>
    <time_frame>The study duration is 7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To monitor the occurrence of diagnosed clinically definite multiple sclerosis (CDMS) in subjects who enter this study at high risk for developing MS following an initial demyelinating event.</measure>
    <time_frame>The study duration is 7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">408</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients previously enrolled in BIogen Idec study C95-812.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients previously enrolled in Biogen Idec study C96-823.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients previously enrolled in Biogen Idec study C97-830.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1a (Avonex)</intervention_name>
    <description>dosage and frequency as per Biogen Idec protocol</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Avonex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have completed (as defined below) one of the following Biogen AVONEX® clinical
             studies and meet the other criteria indicated.

          -  Subjects enrolled from studies C95-812 and C97-830 must have completed their
             respective study within 12 months prior to enrollment in C98-838. Subjects enrolled
             from study C96-823 must have completed the study within 24 months prior to enrollment
             in C98-838.

          -  have not been diagnosed with any other disease that accounts for their neurologic
             symptoms.

        Exclusion Criteria:

          -  History of any significant cardiac, hepatic, pulmonary, or renal disease; immune
             deficiency; or other medical conditions that would preclude therapy with interferon
             beta.

          -  History of severe allergic or anaphylactic reactions or history of hypersensitivity to
             human albumin.

          -  History of seizure within the 3 months prior to enrollment.

          -  Abnormal laboratory results at the screening visit:

          -  History of suicidal ideation or an episode of severe depression within the 3 months
             prior to enrollment into this study.

        Other inclusion and exclusion criteria apply as per Biogen Idec Protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biogen-Idec Investigator</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <last_update_submitted>June 5, 2009</last_update_submitted>
  <last_update_submitted_qc>June 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Biogen Idec MD</name_title>
    <organization>Biogen Idec</organization>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Avonex</keyword>
  <keyword>Interferon beta-1a</keyword>
  <keyword>patients at high risk to develop multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

